These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 31118345)
1. Comparison of biological features between severely immuno-deficient NOD/Shi-scid Il2rg Nagatani M; Kodera T; Suzuki D; Igura S; Fukunaga Y; Kanemitsu H; Nakamura D; Mochizuki M; Kemi M; Tamura K; Kasahara K Exp Anim; 2019 Nov; 68(4):471-482. PubMed ID: 31118345 [TBL] [Abstract][Full Text] [Related]
2. Background data on NOD/Shi-scid IL-2Rγ Kasahara K; Fukunaga Y; Igura S; Andoh R; Saito T; Suzuki I; Kanemitsu H; Suzuki D; Goto K; Nakamura D; Mochizuki M; Yasuda M; Inoue R; Tamura K; Nagatani M J Toxicol Sci; 2017; 42(6):689-705. PubMed ID: 29142168 [TBL] [Abstract][Full Text] [Related]
3. Higher susceptibility of NOD/LtSz-scid Il2rg (-/-) NSG mice to xenotransplanted lung cancer cell lines. Kanaji N; Tadokoro A; Susaki K; Yokokura S; Ohmichi K; Haba R; Watanabe N; Bandoh S; Ishii T; Dobashi H; Matsunaga T Cancer Manag Res; 2014; 6():431-6. PubMed ID: 25364273 [TBL] [Abstract][Full Text] [Related]
4. Higher susceptibility of NOG mice to xenotransplanted tumors. Machida K; Suemizu H; Kawai K; Ishikawa T; Sawada R; Ohnishi Y; Tsuchiya T J Toxicol Sci; 2009 Feb; 34(1):123-7. PubMed ID: 19182442 [TBL] [Abstract][Full Text] [Related]
5. Incidence of spontaneous lymphomas in non-experimental NOD/Shi-scid, IL-2Rγ Yasuda M; Ogura T; Goto T; Yagoto M; Kamai Y; Shimomura C; Hayashimoto N; Kiyokawa Y; Shinohara H; Takahashi R; Kawai K Exp Anim; 2017 Oct; 66(4):425-435. PubMed ID: 28679969 [TBL] [Abstract][Full Text] [Related]
6. Histopathological characteristics of human non-tumor thyroid tissues in a long-term model of adenomatous goiter xenografts in the NOD/Shi-scid, IL-2Rγ(null) mouse. Fujii E; Kato A; Chen YJ; Matsubara K; Ohnishi Y; Suzuki M Exp Toxicol Pathol; 2014 Jul; 66(4):203-9. PubMed ID: 24589354 [TBL] [Abstract][Full Text] [Related]
7. Establishing EGFP congenic mice in a NOD/Shi-scid IL2Rg(null) (NOG) genetic background using a marker-assisted selection protocol (MASP). Suemizu H; Yagihashi C; Mizushima T; Ogura T; Etoh T; Kawai K; Ito M Exp Anim; 2008 Oct; 57(5):471-7. PubMed ID: 18946184 [TBL] [Abstract][Full Text] [Related]
8. Antitumor Effect of Programmed Death-1 (PD-1) Blockade in Humanized the NOG-MHC Double Knockout Mouse. Ashizawa T; Iizuka A; Nonomura C; Kondou R; Maeda C; Miyata H; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Katano I; Ito M; Akiyama Y Clin Cancer Res; 2017 Jan; 23(1):149-158. PubMed ID: 27458246 [TBL] [Abstract][Full Text] [Related]
9. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. Shultz LD; Schweitzer PA; Christianson SW; Gott B; Schweitzer IB; Tennent B; McKenna S; Mobraaten L; Rajan TV; Greiner DL J Immunol; 1995 Jan; 154(1):180-91. PubMed ID: 7995938 [TBL] [Abstract][Full Text] [Related]
10. Human acute leukemia cells injected in NOD/LtSz-scid/IL-2Rgamma null mice generate a faster and more efficient disease compared to other NOD/scid-related strains. Agliano A; Martin-Padura I; Mancuso P; Marighetti P; Rabascio C; Pruneri G; Shultz LD; Bertolini F Int J Cancer; 2008 Nov; 123(9):2222-7. PubMed ID: 18688847 [TBL] [Abstract][Full Text] [Related]
11. Description of a new xenograft model of metastatic neuroblastoma using NOD/SCID/Il2rg null (NSG) mice. Sartelet H; Durrieu L; Fontaine F; Nyalendo C; Haddad E In Vivo; 2012; 26(1):19-29. PubMed ID: 22210712 [TBL] [Abstract][Full Text] [Related]
12. Highly sensitive model for xenogenic GVHD using severe immunodeficient NOG mice. Ito R; Katano I; Kawai K; Hirata H; Ogura T; Kamisako T; Eto T; Ito M Transplantation; 2009 Jun; 87(11):1654-8. PubMed ID: 19502956 [TBL] [Abstract][Full Text] [Related]
13. Data on long-term survival of the NOD/Shi-scid IL-2Rγ Yamashita Y; Sato T; Noishiki K; Kobayashi K; Uchiyama A; Izumi H; Tamura T; Shikamura M; Oinishi Y; Saito M; Kawamata S J Toxicol Sci; 2021; 46(10):453-469. PubMed ID: 34602530 [TBL] [Abstract][Full Text] [Related]
14. Enhanced development of functional human NK cells in NOD-scid-IL2rg Aryee KE; Burzenski LM; Yao LC; Keck JG; Greiner DL; Shultz LD; Brehm MA FASEB J; 2022 Sep; 36(9):e22476. PubMed ID: 35959876 [TBL] [Abstract][Full Text] [Related]
15. NOD-scidIl2rg (tm1Wjl) and NOD-Rag1 (null) Il2rg (tm1Wjl) : a model for stromal cell-tumor cell interaction for human colon cancer. Maykel J; Liu JH; Li H; Shultz LD; Greiner DL; Houghton J Dig Dis Sci; 2014 Jun; 59(6):1169-79. PubMed ID: 24798995 [TBL] [Abstract][Full Text] [Related]
16. Efficient xenoengraftment in severe immunodeficient NOD/Shi-scid IL2rγnull mice is attributed to a lack of CD11c+B220+CD122+ cells. Ito R; Katano I; Ida-Tanaka M; Kamisako T; Kawai K; Suemizu H; Aiso S; Ito M J Immunol; 2012 Nov; 189(9):4313-20. PubMed ID: 23018460 [TBL] [Abstract][Full Text] [Related]
17. Improved engraftment of human spleen cells in NOD/LtSz-scid/scid mice as compared with C.B-17-scid/scid mice. Greiner DL; Shultz LD; Yates J; Appel MC; Perdrizet G; Hesselton RM; Schweitzer I; Beamer WG; Shultz KL; Pelsue SC Am J Pathol; 1995 Apr; 146(4):888-902. PubMed ID: 7717456 [TBL] [Abstract][Full Text] [Related]
18. Pathology of Aging in NOD scid gamma Female Mice. Santagostino SF; Arbona RJR; Nashat MA; White JR; Monette S Vet Pathol; 2017 Sep; 54(5):855-869. PubMed ID: 28355107 [TBL] [Abstract][Full Text] [Related]
20. Immunodeficient NOD-scid IL-2Rγ(null) mice do not display T and B cell leakiness. Katano I; Ito R; Eto T; Aiso S; Ito M Exp Anim; 2011; 60(2):181-6. PubMed ID: 21512274 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]